Delcath Systems, Inc. (DCTH): Price and Financial Metrics
GET POWR RATINGS... FREE!
DCTH Stock Summary
- With a year-over-year growth in debt of 421.72%, Delcath Systems Inc's debt growth rate surpasses 96.79% of about US stocks.
- Over the past twelve months, DCTH has reported earnings growth of 499.49%, putting it ahead of 95.7% of US stocks in our set.
- Delcath Systems Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -81.47%, greater than the shareholder yield of only 4.96% of stocks in our set.
- Stocks that are quantitatively similar to DCTH, based on their financial statements, market capitalization, and price volatility, are LASR, AGYS, MVIS, SEER, and PI.
- DCTH's SEC filings can be seen here. And to visit Delcath Systems Inc's official web site, go to delcath.com.
DCTH Valuation Summary
- In comparison to the median Healthcare stock, DCTH's price/sales ratio is 241.85% higher, now standing at 38.8.
- DCTH's price/sales ratio has moved up 37.8 over the prior 40 months.
- DCTH's price/sales ratio has moved up 37.8 over the prior 40 months.
Below are key valuation metrics over time for DCTH.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| DCTH | 2021-08-31 | 38.8 | 4.9 | -2.9 | -2.3 |
| DCTH | 2021-08-30 | 35.2 | 4.4 | -2.6 | -2.0 |
| DCTH | 2021-08-27 | 35.8 | 4.5 | -2.7 | -2.0 |
| DCTH | 2021-08-26 | 35.7 | 4.5 | -2.7 | -2.0 |
| DCTH | 2021-08-25 | 36.2 | 4.5 | -2.7 | -2.1 |
| DCTH | 2021-08-24 | 34.7 | 4.3 | -2.6 | -2.0 |
DCTH's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- DCTH has a Quality Grade of D, ranking ahead of 7.37% of graded US stocks.
- DCTH's asset turnover comes in at 0.07 -- ranking 160th of 186 Medical Equipment stocks.
- 500 - Internal server error
The table below shows DCTH's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.070 | 0.627 | 39.890 |
| 2021-03-31 | 0.067 | 0.613 | 14.650 |
| 2020-12-31 | 0.081 | 0.611 | 9.684 |
| 2020-09-30 | 0.109 | 0.569 | 1.033 |
| 2020-06-30 | 0.099 | 0.556 | 0.617 |
| 2020-03-31 | 0.132 | 0.563 | 0.458 |
DCTH Price Target
For more insight on analysts targets of DCTH, see our DCTH price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $22.75 | Average Broker Recommendation | 1.25 (Strong Buy) |
DCTH Stock Price Chart Interactive Chart >
DCTH Price/Volume Stats
| Current price | $3.90 | 52-week high | $13.25 |
| Prev. close | $3.99 | 52-week low | $3.49 |
| Day low | $3.90 | Volume | 2,800 |
| Day high | $4.00 | Avg. volume | 28,587 |
| 50-day MA | $4.75 | Dividend yield | N/A |
| 200-day MA | $7.24 | Market Cap | 30.84M |
Delcath Systems, Inc. (DCTH) Company Bio
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.
Latest DCTH News From Around the Web
Below are the latest news stories about Delcath Systems Inc that investors may wish to consider to help them evaluate DCTH as an investment opportunity.
Delcath Systems Announces Move to a Direct Sales & Marketing Model for CHEMOSAT®NEW YORK, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that effective March 1, 2022, it will resume direct responsibility for sales, marketing and distribution activities relating to the CHEMOSAT ® Hepatic Delivery System in Europe (EU, United Kingdom, Norway, Liechtenstein, Switzerland). Since December 2018, medac GmbH, a privately held, multi-national pharmaceutical company based in Germany, has been the licensee for CHEMOSAT in Europe. Delcath and medac are working closely together on an orderly transition of activities. |
Delcath Systems to Present at Upcoming Virtual Investor ConferencesNEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that management will participate at these upcoming virtual investor conferences: The BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference February 17, 2022, at 11:00 AM ETThis is a BTIG hosted event and will not be webcast. Please contact your BTIG representative fo |
Delcath Appoints Anthony Dias as its new Vice President of Finance; Inducement Grant ReportedNEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that the Company has appointed Anthony Dias as its new Vice President of Finance. Mr. Dias brings over 20 years of experience leading finance and operational teams at pharmaceutical, medical device and technology companies. Mr. Dias will oversee all financial aspects of the company, including |
Delcath's Chemosat Hepatic Delivery System Shows Overall Response Rate Of 60.5% In Eye Cancer That Spreads To LiverDelcath Systems Inc's (NASDAQ: DCTH) single-institution retrospective study data on CHEMOSAT Hepatic Delivery System for liver dominant metastatic uveal melanoma (mUM) were published in the journal Melanoma Research. 41 of 81 (50.6%) patients had received other treatments, either systemic or liver-directed, before percutaneous hepatic perfusion (PHP) treatment. 250 PHP procedures were performed in 81 patients. The Company's PHP system is designed to administer high-dose chemotherapy to the liver |
Results of Single Center Study on Delcath’s CHEMOSAT® Hepatic Delivery System Published in Melanoma ResearchRetrospective Study by University Hospital Southampton in metastatic uveal melanoma (mUM) patients with liver dominant disease shows hepatic disease control rate of 88.9%, hepatic response rate of 66.7% and overall response rate of 60.5% After a median follow-up of 12.9 months, median overall progression-free survival (PFS) and median overall survival (OS) were 8.4 and 14.9 months, respectively NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional on |
DCTH Price Returns
| 1-mo | -11.36% |
| 3-mo | -40.46% |
| 6-mo | -50.32% |
| 1-year | -69.17% |
| 3-year | -95.38% |
| 5-year | N/A |
| YTD | -49.68% |
| 2021 | -56.75% |
| 2020 | -15.67% |
| 2019 | -89.16% |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...